The standard of care for treating brain metastases has evolved over time, with whole brain radiotherapy, surgery and stereotactic radiosurgery being used to treat brain metastases. Hamoun Rozati, MBChB, Imperial College London, London, UK, discusses whether the number and volume of brain metastases determine the efficacy of stereotactic radiotherapy. As there are a lack randomized trials assessing patients with more than 10 metastases, a multi-center study was undertaken to compare stereotactic radiotherapy alone in patients with 1-4, 5-10 and 10+ brain metastases. There was no significant difference in patient outcomes across the various cohorts, whereas non-small cell primary cancer and tumor volume affected overall survival. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.